Clinical stage developer and innovative treatment programs providing company for substance abuse problems BioCorRx Inc (OTCMKTS:BICX) is a company that may well be worth looking into at this point in time. The company announced interim positive pharmacokintetic and safety results from the Phase 1 clinical trial of its product BICX104. The product in question is an implantable naltrexone pellet.
On Tuesday, BICX stock fell 0.32% to $1.5550 with more than 2.48K shares, compared to its average volume of 3.13K shares. The stock moved within a range of $1.5300 – 1.5600 after opening trade at $1.5600.
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
The study had been funded by the National Institute of Drug Abuse (NIDA) and it part of the Helping to End Addiction Long-term initiative. The findings had been presented by the principal investigator Dr. Andrew P Mallon on February 21, 2023 at the 4th Annual HEAL Investigator Meeting.
Dr. Mallon noted that although the testing had taken place in healthy people, the data revealed that the product had been tolerated well and there were no adverse effects. All the subjects of the study had been administered with 84 days’ worth of naltrexone therapy. He went on to note that he was looking forward to the completion of the testing of the remaining subjects of the study and expected it to be completed by March 22, 2023. It may be a good idea for investors to keep an eye on it at this point.